Morphic Announces Corporate Highlights and Second Quarter 2021 Financial ResultsGlobeNewsWire • 08/04/21
Earnings Preview: Morphic Holding, Inc. (MORF) Q2 Earnings Expected to DeclineZacks Investment Research • 08/02/21
Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBDGlobeNewsWire • 07/09/21
Strength Seen in Morphic Holding, Inc. (MORF): Can Its 6% Jump Turn into More Strength?Zacks Investment Research • 06/03/21
Morphic Therapeutic to Present Positive Phase 1 Data for MORF-057 at ECCO'21 Virtual CongressGlobeNewsWire • 05/28/21
Morphic Therapeutic to Present at the Jefferies Virtual Healthcare ConferenceGlobeNewsWire • 05/28/21
Morphic Announces Corporate Highlights and First Quarter 2021 Financial ResultsGlobeNewsWire • 04/29/21
Morphic Therapeutic Announces Appointment of Susannah Gray as Member of its Board of DirectorsGlobeNewsWire • 04/28/21
Earnings Preview: Morphic Holding, Inc. (MORF) Q1 Earnings Expected to DeclineZacks Investment Research • 04/28/21
Morphic Therapeutic Announces Pricing of Upsized $245.0 Million Public OfferingGlobeNewsWire • 03/03/21
Morphic Holding, Inc. (MORF) CEO Praveen Tipirneni on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/01/21
Morphic Holding, Inc. (MORF) Reports Q4 Loss, Misses Revenue EstimatesZacks Investment Research • 03/01/21
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057GlobeNewsWire • 03/01/21
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2020GlobeNewsWire • 03/01/21
Will Morphic Holding, Inc. (MORF) Report Negative Q4 Earnings? What You Should KnowZacks Investment Research • 02/18/21